BioVie (BIVI) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioVie (BIVI) has outperformed Medicus Pharma (MDCX) over the past year, losing 35.0% versus a loss of 95.9%. BioVie is the larger company by market cap ($11.4 million vs $140,466), about 80.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | MDCX |
|---|---|---|
| Share price | $1.31 | $0.0937 |
| Market cap | $11.36M | $140.47K |
| 1-day change | +2.19% | -8.04% |
| YTD return | +10.34% | -93.34% |
| 1-year return | -35.03% | -95.86% |
| 5-year return | -99.78% | — |
| EPS (TTM) | $-3.05 | $-119.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.79 | $139.00 |
| 52-week low | $0.82 | $0.084 |
| Distance from 52-week high | -65.49% | -99.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +302.14% | +4702.56% |
| Average volume | 4.60M | 92.96K |
| Shares outstanding | 8.68M | 1.50M |
| Employees | 13 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioVie is about 80.9 times larger than Medicus Pharma by market value ($11.36M vs $140.47K).
- BIVI has outperformed MDCX by 60.8 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
BIVI vs MDCX FAQ
Which is bigger, BioVie or Medicus Pharma?
BioVie (BIVI) is larger, with a market capitalization of $11.36M compared with $140.47K for Medicus Pharma (MDCX).
Which stock has performed better over the past year, BIVI or MDCX?
BIVI returned -35.03% over the past 12 months, compared with -95.86% for MDCX (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.